


Cyclosporin A

Chemical Properties

CAS No. :	59865-13-3
Formula:	C ₆₂ H ₁₁₁ N ₁₁ O ₁₂
Molecular Weight:	1202.61
Appearance:	no data available
Storage:	keep away from moisture Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Cyclosporin A is a naturally occurring cyclic polypeptide that is the active metabolite of a fungus. Cyclosporin A is an immunosuppressant that binds to cyclophilins and inhibits calcineurin (IC ₅₀ =7 nM).
Targets(IC ₅₀)	Antibiotic, Complement System, Phosphatase
In vitro	<p>METHODS: Glioma cell C6 was treated with Cyclosporin A (10 μM) under hypoxic conditions for 4 h. The expression levels of target proteins were measured by Western Blot.</p> <p>RESULTS: 4 h hypoxia induced a large accumulation of endogenous HIF-1α protein, and Cyclosporin A prevented most of the hypoxia-induced HIF-1α stabilization. [1]</p> <p>METHODS: Human colon cancer cells CACO-2 were treated with Cyclosporin A (2 μM) for 24-72 h. The cell cycle was detected by Flow Cytometry.</p> <p>RESULTS: Accumulation of cells was detected in the G₀/G₁ phase after treatment with Cyclosporin A. The RESULTS were summarized in the following table. [2]</p>
In vivo	<p>METHODS: To assay activity against muscle disease in vivo, Cyclosporin A (5 mg/kg in olive oil) was injected intraperitoneally into myopathic Col6a1^{-/-} mice twice daily for ten days.</p> <p>RESULTS: Cyclosporin A affected satellite cell activity and triggered regenerative fiber formation in Col6a1^{-/-} mice. [3]</p> <p>METHODS: To detect the effects on ischemia-reperfusion injury (IRI), Cyclosporin A (3 mg/kg, 1 h or 10 min before ischemia; 10 mg/kg, 10 min before ischemia) was intraperitoneally injected into ischemia-reperfused C57BL/6J mice.</p> <p>RESULTS: Mortality and renal function were significantly higher in the Cyclosporin A 10 mg/kg-10 min and Cyclosporin A 3 mg/kg-1 h groups than in the Cyclosporin A 3 mg/kg-10 min group. [4]</p>
Kinase Assay	<p>Phosphatase Assay: Purified bovine brain calcineurin and calmodulin are purchased. Reaction mixtures with purified enzyme contains 100 nM calcineurin, 100 nM calmodulin, and 5 μM 32P-labeled phosphopeptide, in 60 μl (total volume) of assay buffer containing 20 mM Tris (pH 8), 100 mM NaCl, 6 mM MgCl₂, 0.5 mM dithiothreitol, 0.1 mg of bovine serum albumin per ml, and either 0.1 mM CaCl₂ or 5 mM EGTA. Reaction mixtures with cell lysates contains 20 μl of undiluted lysate, 5 μM 32P-labeled phosphopeptide, and 40 μl of assay buffer. Where indicated, reaction mixtures contains 50 μM peptide 412 or 413 and/or 500 nM okadaic acid, a specific inhibitor of phosphatases 1 and 2A; 500 nM okadaic acid is sufficient for inhibition of Ca²⁺-</p>

independent phosphatases, whereas higher concentrations partially inhibit Ca²⁺-dependent activity as well. After 15 min at 30°C, reactions are terminated by the addition of 0.5 ml of 100 mM potassium phosphate buffer (pH 7.0) containing 5% trichloroacetic acid. Free inorganic phosphate is isolated by Dowex cation-exchange chromatography and quantitated by scintillation counting as described.

Cell Research	Immunosuppressive agents are dissolved in ethanol at concentrations 1000-fold more than the concentration desired for cell treatments. Cells (106) are suspended in 1 ml of complete medium in microcentrifuge tubes; 1 µl of ethanol or of the ethanolic solution of Cyclosporin A is added, and the cells are incubated at 37°C for 1 hr. Cells are washed twice with 1 ml of PBS on ice and lysed in 50 µl of hypotonic buffer containing 50 mM Tris (pH 7.5); 0.1 mM EGTA; 1 mM EDTA; 0.5 mM dithiothreitol; and 50 µg of phenylmethylsulfonyl fluoride, 50 µg of soybean trypsin inhibitor, 5 µg of leupeptin, and 5 µg of aprotinin per ml. Lysates are subjected to three cycles of freezing in liquid nitrogen followed by thawing at 30°C and then are centrifuged at 4°C for 10 min at 12,000×g.(Only for Reference)
---------------	--

Solubility Information

Solubility	DMSO: 60 mg/mL (49.89 mM),Sonication is recommended. Ethanol: 60.1 mg/mL (49.97 mM),Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 12.03 mg/mL (10 mM),Suspension. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.8315 mL	4.1576 mL	8.3152 mL
5 mM	0.1663 mL	0.8315 mL	1.663 mL
10 mM	0.0832 mL	0.4158 mL	0.8315 mL
50 mM	0.0166 mL	0.0832 mL	0.1663 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

- D'Angelo G, et al. Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation. *J Biol Chem*. 2003 Apr 25;278(17):15406-11.
- Bao, Shixiang, et al. TGF- β 1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma. *Frontiers in Oncology*. 11 (2021): 2516.
- Song J, Zou D, Zhao X, et al. Bufalin inhibits human diffuse large B-cell lymphoma tumorigenesis by inducing cell death through the Ca²⁺/NFATC1/cMYC pathway. *Carcinogenesis*. 2020
- Werneck MB, et al. Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. *Cell Cycle*. 2012 Nov 1;11(21):3997-4008.
- Gattazzo F, et al. Cyclosporin A Promotes in vivo Myogenic Response in Collagen VI-Deficient Myopathic Mice. *Front Aging Neurosci*. 2014 Sep 15;6:244.
- Liu J, Giri B R, Chen Y, et al. Schistosoma japonicum IAP and Teg20 safeguard tegumental integrity by inhibiting cellular apoptosis. *PLoS Neglected Tropical Diseases*. 2018 Jul 25;12(7):e0006654
- Lemoine S, et al. Dose and timing of injections for effective cyclosporine A pretreatment before renal ischemia reperfusion in mice. *PLoS One*. 2017 Aug 10;12(8):e0182358.
- Ren Y, Tong X, Zhao Y, et al. Dolabrane-Type Diterpenoids with Immunosuppressive Activity from *Koilocarpus hainanense*. *Journal of Natural Products*. 2022
- Zheng B X, Long W, Zheng W, et al. Mitochondria-Selective Dicationic Small-Molecule Ligand Targeting G-Quadruplex Structures for Human Colorectal Cancer Therapy. *Journal of Medicinal Chemistry*. 2024
- Nicolli A, et al. *J Biol Chem*, 1996, 271(4), 2185-2192.
- He Y, Xu D, Zhang J, et al. Bergenin, the main active ingredient of *Bergenia purpurascens*, attenuates Th17 cell differentiation by downregulating fatty acid synthesis. *The FASEB Journal*. 2024, 38(19): e70095.
- Liu J, Giri B R, Chen Y, et al. Schistosoma japonicum IAP and Teg20 safeguard tegumental integrity by inhibiting cellular apoptosis[J]. *PLoS neglected tropical diseases*. 2018 Jul 25;12(7):e0006654.
- Wu Y, Tang K, Wang C, et al. Establishment of interpretable cytotoxicity prediction models using machine learning analysis of transcriptome features. *Acta Pharmaceutica Sinica B*. 2025
- Song J, Zou D, Zhao X, et al. Bufalin inhibits human diffuse large B-cell lymphoma tumorigenesis by inducing cell death through the Ca²⁺/NFATC1/cMYC pathway[J]. *Carcinogenesis*. 2020
- Song J, Zou D, Zhao X, et al. Bufalin inhibits human diffuse large B cell lymphoma tumorigenesis by inducing cell death through the Ca²⁺/NFATC1/cMYC pathway[J]. *Carcinogenesis*. 2020

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481